Nilevar (norethandrolone) was synthesized and approved by G.D. Searle as the first orally-active anabolic steroid in 1956. Norethandrolone has moderate progestagenic activity. I don’t have information on whether Winstrol counteracts this, as appears to be the case with Anadrol, but in any case Nilevar is not considered a particularly useful drug for male bodybuilders. For female bodybuilders, it is probably an average synthetic, comparable to Dianabol. It shares the liver toxicity issues common to 17-alkylated steroids.
Nilevar probably has low conversion to estrogen (contrary to claims made elsewhere).
Norethandrolone is the chemical name of active ingredient in Nilevar. Nilevar was originally a registered trademark of Searle Laboratories in the United States and/or other countries prior to cancellation.
About the author
Bill Roberts is an internationally-recognized expert on anabolic steroids and performance-enhancing drugs (PEDs). He received a bachelor degree in Microbiology and Cell Science and completed the educational and research requirements for a PhD in Medicinal Chemistry at a major American university.
Bill entered the nutritional supplement industry prior to completing his doctoral thesis but his education was invaluable so far as being able to design/improve nutritional supplement compounds, since it was in the field of designing drug molecules and secondarily some work in transdermal delivery.
His education was not specifically "geared" toward anabolic steroids other than expertise with pharmacological principles having broad applications. This has allowed Bill to provide unique insight into the field of anabolic pharmacology with knowledge of points which he would not have known otherwise.